Teva Pharmaceutical Industries Limited (TEVA)
After hours:
| Previous close | 13.98 |
| Open | 13.92 |
| Bid | 13.66 x 3100 |
| Ask | 14.05 x 3200 |
| Day's range | 13.81 - 14.13 |
| 52-week range | 7.09 - 14.47 |
| Volume | |
| Avg. volume | 9,279,165 |
| Market cap | 15.948B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Nov 2017 |
| 1y target est | 15.50 |
Business WireTeva to Present at the 2024 Bank of America Healthcare Conference
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time).
Insider MonkeyCorcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corcept Therapeutics Incorporated beats earnings expectations. Reported EPS is $0.2503, expectations were $0.21. Corcept Therapeutics Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank […]
Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2023 Healthy Future Report, sharing its actions to promote healthy people, a healthy planet and a healthy business. The report unveils new targets to achieve net zero emissions across Teva’s operations and value chain by 2045 and 100% renewable electricity across all Teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity building
